Healthy pregnant women ≤49 years of age who are between 24 0/7 and 36 0/7 weeks of gestation on the day of planned vaccination, with an uncomplicated, singleton pregnancy, and who have no known increased risk of complications.
Had a fetal anomaly ultrasound examination with no significant fetal abnormalities observed.
Documented negative human immunodeficiency virus (HIV) antibody test, syphilis test, and hepatitis B virus (HBV) surface antigen test during this pregnancy and prior to randomization.
Capable of giving personal signed informed consent.
Willing to give informed consent for her infant to participate in the study.
\- Evidence of a signed and dated ICD signed by the parent(s)/legally authorized representative or legal guardian
You may not be if
Prepregnancy body mass index (BMI) of \>40 kg/m2.
Current pregnancy complications or abnormalities that may increase the risk associated with the participation in and completion of the study.
Prior pregnancy complications or abnormalities that, based on the investigator's judgment, may increase the risk associated with the participation in and completion of the study.
History of microbiologically proven invasive disease caused by GBS in the current pregnancy.
A known or suspected infection during the current pregnancy that may increase the risk of complications in pregnancy (eg, active tuberculosis, syphilis, primary genital herpes simplex, malaria).
\- Children or grandchildren who are direct descendants of investigator site staff or sponsor and sponsor delegate employees directly involved in the conduct of the study.
\- Children with a known or suspected contraindication to any vaccine administered in the infant vaccine immunogenicity subset.
Refer to the study contact for further eligibility details
